Form 4: Arcutis Biotherapeutics Director Howard G. Welgus Sells 10,000 Shares Under 10b5-1 Trading Plan

Director Howard G. Welgus sold 10,000 shares of Arcutis Biotherapeutics (ARQT) at an average price of $13.0048 on March 3, 2025, under a pre-arranged 10b5-1 trading plan.

Summary

• On March 3, 2025, Howard G. Welgus, a director of Arcutis Biotherapeutics, Inc. (ARQT), sold 10,000 shares of common stock.
• The sale was executed at a weighted average price of $13.0048 per share.
• The transactions occurred under a 10b5-1 trading plan adopted on March 5, 2024, with a plan end date of May 30, 2025.
• Following the reported transaction, Welgus directly owns 131,944 shares of Arcutis Biotherapeutics.
• The shares were sold in multiple transactions at prices ranging from $12.68 to $13.69.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it reports a routine stock sale under a pre-arranged trading plan. It doesn't inherently indicate positive or negative sentiment towards the company's prospects.

Future Outlook

The document does not contain any specific forward-looking statements regarding the company's future performance.

Industry Context

This is a routine disclosure of an insider stock sale under a pre-arranged trading plan, which is a common practice among corporate executives and directors. It doesn't necessarily reflect a change in the insider's view of the company's prospects.

Comparison to Industry Standards

• Insider sales are a common occurrence in publicly traded companies, especially in the biotechnology sector where stock options and equity-based compensation are prevalent.
• The use of 10b5-1 trading plans is a standard practice to avoid accusations of insider trading, as these plans are established in advance and operate independently of any material non-public information the insider may possess.
• Comparing this transaction to similar insider sales at companies like Amgen (AMGN) or Regeneron (REGN) would require analyzing the size of the sale relative to the insider's holdings and the company's market capitalization.

Stakeholder Impact

• The stock sale could have a minor negative impact on shareholder sentiment, although it is unlikely to be significant given that it was conducted under a pre-arranged trading plan.

Key Dates